

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6373633/publications.pdf>

Version: 2024-02-01

135  
papers

4,151  
citations

87843

38  
h-index

175177

52  
g-index

136  
all docs

136  
docs citations

136  
times ranked

5254  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant <i>P. falciparum</i> strains. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5384-5388.	1.0	142
2	Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. <i>Progress in Neurobiology</i> , 2017, 151, 4-34.	2.8	128
3	Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT <sub>3</sub> Receptor Agonists: Synthesis, Further Structure-Activity Relationships, and Biological Studies. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4362-4379.	2.9	103
4	Synthesis and Pharmacological Evaluation of Potent and Highly Selective D <sub>3</sub> Receptor Ligands: Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D <sub>3</sub> /D <sub>2</sub> Receptors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3822-3839.	2.9	90
5	Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 864-879.	2.6	80
6	Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D <sub>3</sub> and Serotonin 5-HT <sub>1A</sub> and 5-HT <sub>2A</sub> Receptors: Design, Synthesis, and Effects on Behavior. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 151-169.	2.9	79
7	Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13466-13513.	2.9	75
8	Design, Synthesis, and Structure-Activity Relationship Studies of 4-Quinoliny- and 9-Acrydinylhydrazones as Potent Antimalarial Agents. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1333-1343.	2.9	73
9	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2612-2632.	2.9	70
10	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 23-39.	2.9	69
11	Dopamine D <sub>3</sub> Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. <i>Frontiers in Neuroscience</i> , 2016, 10, 451.	1.4	66
12	Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1919-1929.	2.9	65
13	Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10387-10404.	2.9	58
14	Structure-based discovery of the first non-covalent inhibitors of <i>Leishmania major</i> trypanothione peroxidase by high throughput docking. <i>Scientific Reports</i> , 2015, 5, 9705.	1.6	58
15	Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3154-3170.	2.9	56
16	Combining 4-Aminoquinoline- and Clotrimazole-Based Pharmacophores toward Innovative and Potent Hybrid Antimalarials. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 502-513.	2.9	55
17	Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 4367-4377.	2.9	53
18	Computational Tool for Fast in silico Evaluation of hERG K <sup>+</sup> Channel Affinity. <i>Frontiers in Chemistry</i> , 2017, 5, 7.	1.8	52

#	ARTICLE	IF	CITATIONS
19	The Citrus Flavonoid Naringenin Protects the Myocardium from Ageing-Dependent Dysfunction: Potential Role of SIRT1. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-15.	1.9	52
20	Disease-Modifying Anti-Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with Amyloid Aggregation. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 624-632.	1.9	51
21	Organic Isothiocyanates as Hydrogen Sulfide Donors. <i>Antioxidants and Redox Signaling</i> , 2020, 32, 110-144.	2.5	51
22	Development of antitubercular compounds based on a 4-quinolyhydrazone scaffold. Further structure-activity relationship studies. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6063-6072.	1.4	50
23	Discovery and Cardioprotective Effects of the First Non-Peptide Agonists of the G Protein-Coupled Prokineticin Receptor-1. <i>PLoS ONE</i> , 2015, 10, e0121027.	1.1	50
24	Verbascoside Inhibits Promastigote Growth and Arginase Activity of <i>Leishmania amazonensis</i> . <i>Journal of Natural Products</i> , 2016, 79, 1459-1463.	1.5	47
25	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9578-9597.	2.9	46
26	Clotrimazole Scaffold as an Innovative Pharmacophore Towards Potent Antimalarial Agents: Design, Synthesis, and Biological and Structure-Activity Relationship Studies. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1278-1294.	2.9	45
27	Pyrroloquinoline hydrazones as fluorescent probes for amyloid fibrils. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 5137.	1.5	44
28	Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis, and Biological Evaluation of Novel, Potent, and Broad Spectrum NNRTIs with Antiviral Activity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7153-7165.	2.9	43
29	Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure-Activity Relationships, in Vivo Studies, and Preliminary Toxicity Profiling. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6948-6967.	2.9	43
30	Novel Analgesic/Anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3191-3206.	2.9	43
31	Development of Potent Inhibitors of the <i>Mycobacterium tuberculosis</i> Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. <i>ChemMedChem</i> , 2018, 13, 422-430.	1.6	43
32	Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues. <i>Journal of Organic Chemistry</i> , 2010, 75, 2333-2340.	1.7	42
33	An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction. <i>Computational Biology and Chemistry</i> , 2019, 83, 107105.	1.1	42
34	Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold: Exploring an Innovative Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 595-598.	2.9	40
35	Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1178-1182.	1.3	40
36	Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. <i>MedChemComm</i> , 2015, 6, 357-362.	3.5	39

#	ARTICLE	IF	CITATIONS
37	Identification of novel fluorescent probes preventing PrP Sc replication in prion diseases. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 859-873.	2.6	39
38	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 127-138.	2.6	39
39	The Structural Evolution of $\beta$ -Secretase Inhibitors: A Focus on the Development of Small-Molecule Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 1787-1807.	1.0	39
40	Specific Targeting of Peripheral Serotonin 5-HT <sub>3</sub> Receptors. Synthesis, Biological Investigation, and Structure-Activity Relationships. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3548-3562.	2.9	38
41	Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABA <sub>B</sub> Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 340, 529-538.	1.3	38
42	Rational design of the first difluorostatone-based PfSUB1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3582-3586.	1.0	38
43	Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structure-Activity Relationship, Molecular Modeling, and Biological Studies. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 344-359.	2.9	36
44	iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated $\alpha$ -tubulin defect which improves after iHDAC6 treatment in Rett syndrome. <i>Experimental Cell Research</i> , 2018, 368, 225-235.	1.2	36
45	Computational Approaches for Drug Discovery. <i>Molecules</i> , 2019, 24, 3061.	1.7	36
46	Novel, Potent, and Selective Quinoxaline-Based 5-HT <sub>3</sub> Receptor Ligands. 1. Further Structure-Activity Relationships and Pharmacological Characterization. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6946-6950.	2.9	35
47	Structural characterization of <i>Giardia duodenalis</i> thioredoxin reductase (g TrxR) and computational analysis of its interaction with NBDHEX. <i>European Journal of Medicinal Chemistry</i> , 2017, 135, 479-490.	2.6	35
48	A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. <i>Molecules</i> , 2019, 24, 4373.	1.7	34
49	First dual AK/GSK-3 $\beta$ inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 138, 438-457.	2.6	33
50	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 433-457.	1.0	33
51	Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6898-6915.	2.9	32
52	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. <i>Frontiers in Chemistry</i> , 2019, 7, 574.	1.8	32
53	Dietary polyphenols rutin, taxifolin and quercetin related compounds target <i>Leishmania amazonensis</i> arginase. <i>Food and Function</i> , 2019, 10, 3172-3180.	2.1	32
54	Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 547-555.	2.6	31

#	ARTICLE	IF	CITATIONS
55	Discovery of GPCR ligands for probing signal transduction pathways. <i>Frontiers in Pharmacology</i> , 2014, 5, 255.	1.6	31
56	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 290-320.	2.6	31
57	Pharmacophore Modeling for Qualitative Prediction of Antiestrogenic Activity. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 2489-2497.	2.5	30
58	Quinolyhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5317-5321.	1.0	28
59	Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 85-94.	2.6	28
60	3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 67, 344-351.	2.6	28
61	Structure-activity relationships study of isothiocyanates for H2S releasing properties: 3-Pyridyl-isothiocyanate as a new promising cardioprotective agent. <i>Journal of Advanced Research</i> , 2021, 27, 41-53.	4.4	28
62	An Efficient Approach to Chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as Peptidomimetic Scaffolds. <i>Journal of Organic Chemistry</i> , 2008, 73, 8458-8468.	1.7	27
63	Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1401-1420.	2.9	27
64	Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-ylxoacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5391-5402.	2.9	27
65	Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 99-106.	2.6	27
66	Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues. <i>European Journal of Medicinal Chemistry</i> , 2018, 150, 698-718.	2.6	27
67	Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 228-236.	1.3	27
68	Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5213-5216.	1.0	26
69	Development of novel cyclic peptides as pro-apoptotic agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 117, 301-320.	2.6	26
70	Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors as Multistage Antischistosomal Agents. <i>ACS Infectious Diseases</i> , 2020, 6, 100-113.	1.8	26
71	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9960-9988.	2.9	26
72	Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4803-4807.	2.9	25

#	ARTICLE	IF	CITATIONS
73	Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5949-5953.	2.9	25
74	Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials. <i>Tetrahedron Letters</i> , 2009, 50, 5719-5722.	0.7	24
75	Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2268-2276.	1.3	23
76	1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6614-6618.	2.9	22
77	Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. <i>European Journal of Medicinal Chemistry</i> , 2021, 212, 112998.	2.6	22
78	Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. <i>Computers in Biology and Medicine</i> , 2021, 137, 104808.	3.9	22
79	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrene-4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. <i>Medicinal Chemistry</i> , 2019, 15, 755-770.	0.7	22
80	Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1 <i>H</i> -Cyclopentapyrimidin-2,4(1 <i>H</i> ,3 <i>H</i> )-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4793-4805.	2.9	21
81	Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylprrrol-3-substituted scaffold. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115045.	1.4	21
82	Amyloid $\beta$ fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil. <i>Food and Function</i> , 2020, 11, 8122-8132.	2.1	21
83	Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. <i>Cells</i> , 2022, 11, 471.	1.8	21
84	Microwave-assisted synthesis of 4-quinolyhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives. <i>Tetrahedron Letters</i> , 2008, 49, 2074-2077.	0.7	20
85	( <i>S</i> )-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2124-2130.	2.9	20
86	Cinnamic acids derived compounds with antileishmanial activity target <i>Leishmania amazonensis</i> arginase. <i>Chemical Biology and Drug Design</i> , 2019, 93, 139-146.	1.5	20
87	Targeting clinically-relevant metallo- $\beta$ -lactamases: from high-throughput docking to broad-spectrum inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 98-109.	2.5	19
88	Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. <i>Future Medicinal Chemistry</i> , 2016, 8, 1573-1587.	1.1	19
89	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. <i>ChemMedChem</i> , 2018, 13, 2090-2103.	1.6	19
90	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. <i>RSC Advances</i> , 2016, 6, 64651-64664.	1.7	19

#	ARTICLE	IF	CITATIONS
91	Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant <i>P. falciparum</i> strains. <i>Synthesis and molecular modeling</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3535-3539.	1.0	18
92	A stereoselective approach to peptidomimetic BACE1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 233-247.	2.6	17
93	In silico study of subtilisin-like protease 1 (SUB1) from different <i>Plasmodium</i> species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2016, 64, 121-130.	1.3	17
94	MicroRNA-Based Multitarget Approach for Alzheimer's Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9695-9704.	2.9	17
95	Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1224-1228.	2.9	15
96	Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 85-89.	1.0	15
97	Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 492-495.	1.0	15
98	<i>Plasmodium falciparum</i> subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. <i>RSC Advances</i> , 2015, 5, 22431-22448.	1.7	15
99	Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5412-5418.	1.0	15
100	Cinnamides Target <i>Leishmania amazonensis</i> Arginase Selectively. <i>Molecules</i> , 2020, 25, 5271.	1.7	15
101	Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. <i>Molecules</i> , 2020, 25, 1952.	1.7	15
102	Synthesis and biological evaluation of a new class of benzothiazines as neuroprotective agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 614-630.	2.6	14
103	Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111674.	2.6	14
104	Malaria Chemotherapy: Recent Advances in Drug Development. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2010, 5, 195-225.	0.5	13
105	From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for <i>P. falciparum</i> . <i>RSC Advances</i> , 2014, 4, 4769-4781.	1.7	13
106	Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. <i>ChemMedChem</i> , 2017, 12, 2074-2085.	1.6	13
107	Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II). <i>Bioorganic Chemistry</i> , 2019, 89, 103020.	2.0	13
108	Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1716-1736.	1.7	12

#	ARTICLE	IF	CITATIONS
109	Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer's Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 648-658.	1.1	12
110	Virtual Combinatorial Library Screening of Quinadoline B Derivatives against SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>Computation</i> , 2022, 10, 7.	1.0	12
111	Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate. <i>Malaria Journal</i> , 2011, 10, 348.	0.8	11
112	A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues. <i>Tetrahedron Letters</i> , 2013, 54, 5387-5390.	0.7	11
113	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114409.	2.6	11
114	A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides. <i>Tetrahedron Letters</i> , 2013, 54, 1233-1235.	0.7	10
115	Dealing with schistosomiasis: Current drug discovery strategies. <i>Annual Reports in Medicinal Chemistry</i> , 2019, 53, 107-138.	0.5	10
116	Retinitis Pigmentosa and Retinal Degenerations: Deciphering Pathways and Targets for Drug Discovery and Development. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2173-2191.	1.7	10
117	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12209-12220.	2.0	10
118	Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity. <i>Molecules</i> , 2022, 27, 463.	1.7	10
119	In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and therapeutic potential of existing antiviral drugs. <i>Computers in Biology and Medicine</i> , 2021, 135, 104591.	3.9	9
120	Ionotropic Glutamate Receptor GluA2 in Complex with Bicyclic Pyrimidinedione-Based Compounds: When Small Compound Modifications Have Distinct Effects on Binding Interactions. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1791-1800.	1.7	8
121	HCV-targeted Antivirals: Current Status and Future Challenges. <i>Current Pharmaceutical Design</i> , 2014, 20, 3445-3464.	0.9	8
122	A light in the dark: state of the art and perspectives in optogenetics and optopharmacology for restoring vision. <i>Future Medicinal Chemistry</i> , 2019, 11, 463-487.	1.1	7
123	Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the $\alpha$ -primer grip-region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. <i>Biochemical Pharmacology</i> , 2008, 76, 156-168.	2.0	6
124	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy. <i>European Journal of Medicinal Chemistry</i> , 2022, 235, 114274.	2.6	6
125	Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs. <i>Tetrahedron Letters</i> , 2016, 57, 920-923.	0.7	5
126	A Jovic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents. <i>Tetrahedron Letters</i> , 2018, 59, 4466-4470.	0.7	5



#	ARTICLE	IF	CITATIONS
127	Development of In Vitro Corneal Models: Opportunity for Pharmacological Testing. <i>Methods and Protocols</i> , 2020, 3, 74.	0.9	5
128	Identification of novel SIRT1 activators endowed with cardioprotective profile. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 165, 105930.	1.9	5
129	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3935-3938.	1.0	4
130	Design, synthesis and biological evaluation of 7-substituted 4-phenyl-6H-imidazo[1,5-a]thieno[3,2-f][1,4]diazepines as safe anxiolytic agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 200, 112405.	2.6	4
131	Structure-Based Design of Biologically Active Compounds. <i>Molecules</i> , 2020, 25, 3115.	1.7	3
132	Design and Synthesis of New Oligopeptidic Parvulin Inhibitors. <i>ChemMedChem</i> , 2022, , .	1.6	3
133	In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). <i>Computation</i> , 2022, 10, 69.	1.0	3
134	Artificial Intelligence in Translational Medicine. <i>International Journal of Translational Medicine</i> , 2021, 1, 223-285.	0.1	2
135	Synthetic studies toward bicyclic endoperoxides presenting polar side chains. <i>Tetrahedron Letters</i> , 2018, 59, 4330-4333.	0.7	1